首页> 美国卫生研究院文献>California Medicine >Revascularization in coronary artery disease. A review of randomized trial data.
【2h】

Revascularization in coronary artery disease. A review of randomized trial data.

机译:冠状动脉疾病的血运重建。随机试验数据的审查。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Since the advent of bypass surgery in the late 1960s and catheter-based intervention in the late 1970s, the treatment of coronary artery disease has been revolutionized by the concept of revascularization. Surveys have demonstrated that the practice patterns around the world and within the US are inconsistent for these important treatment options and are often driven by availability and economics rather than evidence-based data. In addition, the studies examining the use of medical therapy, balloon angioplasty, atherectomy, coronary stenting, and bypass surgery are consistently lagging behind the technological advances in this field. This article reviews the data that randomized trials and meta-analyses provide to compare these modalities. We attempt to provide a framework for reasoned clinical decision making to help guide patient care. While the breakpoints between the medicine bottle, cath lab, and operating room will continue to evolve, we offer a revascularization strategy for patient subgroups based on what clinical data supports.
机译:自从1960年代末旁路手术和1970年代末基于导管的干预问世以来,血运重建概念彻底改变了冠状动脉疾病的治疗方法。调查表明,世界范围内和美国的实践模式与这些重要的治疗方案均不一致,并且通常由可用性和经济性驱动,而不是基于证据的数据。此外,检查药物治疗,球囊血管成形术,旋切术,冠状动脉支架置入术和搭桥手术的使用的研究始终落后于该领域的技术进步。本文回顾了随机试验和荟萃分析提供的数据,以比较这些方式。我们尝试提供合理的临床决策框架,以帮助指导患者护理。虽然药瓶,导管实验室和手术室之间的断点将继续发展,但我们会根据临床数据的支持为患者亚组提供血运重建策略。

著录项

  • 期刊名称 California Medicine
  • 作者

    C R Keenan; T M Chou;

  • 作者单位
  • 年(卷),期 1998(168),4
  • 年度 1998
  • 页码 280–285
  • 总页数 6
  • 原文格式 PDF
  • 正文语种
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号